

<b>Protocol</b>	<b>Clinical Description</b>	<b>Medication</b>	<b>Brand (if applicable)</b>	<b>Drug formulary</b>	<b>Study Phase</b>	<b>Status</b>
BIO89-100-131	NASH	Pegozafermin		SQ injection	3	Enrolling
BIO89-100-132	NASH Cirrhosis	Pegozafermin		SQ injection	3	Enrolling
CB8025-41837	PBC	seladelpar	Livedelzi	PO	3	Enrolling
GA45329	UC	RO7790121		IV, then SQ injection	3	Enrolling
REC-4881-201	FAP	REC-4881		PO	1b/2	Enrollment on hold
CLIN-60190-454	PBC	Elafibranor	Iqirvo	PO	3	enrolling
		Bemnifosbuvir-Ruzasvir vs				
AT-01B-007	Hepatitis C	Sofosbuvir-Velpatasvir	vs Epclusa	PO	3	Enrolling
GA45331	Crohn's	RO7790121		IV, then SQ injection	3	Enrolling
CRV-HCC-001	HCC Screening					Enrolling
M25-540	UC	Risankizumab vs Vedolizumab	Skyrizi vs Entyvio	IV/SQ for R, IV for V	3b	Enrolling
I6T-MC-AMCD	UC	Mirikizumab +/- Tirzepatide	OmvoH +/- Zepbound	IV/SQ for M, SQ for T	3b	Enrolling
I6T-MC_AMCE	Crohn's	Mirikizumab +/- Tirzepatide	OmvoH +/- Zepbound	IV/SQ for M, SQ for T	3b	Enrolling
GA45330	UC	RO7790121		IV, then SQ injection	3	Enrolling
MT-100-201	UC/Crohn's	MT-501		PO	2	Enrolling
Endo-ext	Barrett's esophagus					Enrolling
RD-2501	Colorectal Cancer					Enrolling
				PO for M, IV then SQ for		
J6E-MC-KWAN	UC	MORF-057 + Mirikizumab	OmvoH	Miri	2	Upcoming
N1T-MC-MALO	MASLD	Tirzepatide vs Retatrutide	Zepbound vs.	SQ injection	3	Upcoming
EoE-201	Eosinophilic Esophagitis	Vonoprazan	Voquenza	PO	2	Upcoming